Drug Topics
JULY 3, 2025
As state-level PBM reform heats up amid dire situations for many retail pharmacies, Walgreens Chief Pharmacy Officer Rick Gates joins Drug Topics to discuss ongoing industry challenges.
STAT
JULY 3, 2025
Last fall, a group of experts advising the U.S. Food and Drug Administration debated for two days on how to regulate generative artificial intelligence tools in medicine. One report presented at the meeting showed that a generative AI tool supposedly used by 40% of the radiology practices in the U.S. produced clinically significant errors in one of every 21 reports.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 3, 2025
An expert discusses how pharmacists should follow CDC immunization schedules for different age groups and use shared clinical decision-making for patients with prior vaccination history, while considering contraindications primarily related to severe allergic reactions to vaccine components.
STAT
JULY 3, 2025
Recently, the Department of Health and Human Services floated new standards for vaccine approvals, rescinded longstanding Covid-19 vaccine recommendations for healthy children and pregnant women, and fired all 17 members of the Centers for Disease Control and Prevention’s vaccine advisory committee. These actions represent a significant shift in the federal government’s approach to vaccine policy and the safeguarding of the public’s health.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
JULY 3, 2025
Embedded as the cornerstone of microbiological quality are processes that have remained the same for over a century, unchanged from their early beginnings. To achieve optimal detectability and considerably lower risk to patients, the traditional sterility test requires a minimum of 14 days of incubation, and sometimes even longer if the test sample renders media turbid and subculturing is required to overcome visual interference.
STAT
JULY 3, 2025
There’s been much discussion and debate about the cuts to Medicaid eligibility that Congress just passed and, in particular, what they may mean for current Medicaid recipients. A key piece of evidence in this debate has been results from the Oregon Health Insurance Experiment (OHIE ), a randomized trial, which I helped lead, examining the impact of covering low-income uninsured adults with Medicaid for one to two years.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
JULY 3, 2025
Over 660 million pilgrims gathered at the Maha Kumbh Mela in Prayagraj, India, this past February, and I’m now seeing the downstream consequences in my California clinic. This year, I’ve treated several Americans who returned ill after ritual bathing in India’s sacred river. Their diagnoses have ranged from typhoid fever and multidrug-resistant E. coli to persistent giardiasis and polymicrobial gastroenteritis.
Pharmacy Times
JULY 3, 2025
An expert discusses how the 5 FDA-approved pneumococcal vaccines differ, with newer conjugate vaccines like PCV20 and PCV21 offering broader serotype coverage and better immune memory compared with the older polysaccharide vaccine, though geographic factors may influence vaccine selection.
Pharmafile
JULY 3, 2025
Ferring Pharmaceuticals has reported that a conventional 15µg/day starting dose of follitropin delta (Rekovelle) provides comparable efficacy and safety to a standard 225IU/day dose of follitropin alfa in women undergoing ovarian stimulation for fertility treatments: in vitro fertilisation or intracytoplasmic sperm injection. This reinforces the clinical evidence base for follitropin delta, the only recombinant follicle-stimulating […] The post Ferring strengthens evidence for flexible dos
The Checkup by Singlecare
JULY 3, 2025
Wegovy is a prescription medication that’s making headlines for its effectiveness in helping people lose weight and manage obesity. As a GLP-1 receptor agonist , it’s FDA approved not only for weight management but also for reducing the risk of heart attacks and strokes in those with cardiovascular disease. The active ingredient, semaglutide, is delivered through a once-weekly injection and works best when paired with healthy eating and regular exercise.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JULY 3, 2025
Dizal gets US approval for an oral therapy for EGFR exon 20-mutated NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant
DiversifyRx
JULY 3, 2025
Real talk on getting stuff done as an independent pharmacy owner. Let’s be honest—pharmacy owners are some of the hardest-working people on the planet. You’re juggling scripts, managing teams, navigating PBM nonsense, and oh yeah, trying to grow your business. But somewhere between the whirlwind of daily operations and your big dreams… your plans stall out.
pharmaphorum
JULY 3, 2025
Regeneron's bid to join the crowded US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised
The Checkup by Singlecare
JULY 3, 2025
Diltiazem is a prescription pill used to control blood pressure, lower pulse rates, and prevent angina. A member of the calcium channel blocker class of medications, diltiazem has a long track record for the treatment of hypertension and heart disease. Obtaining the drug should be quite doable based on its generic availability. The price of 30, 120 mg capsules of 24-hour extended-release diltiazem is about $70.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
European Pharmaceutical Review
JULY 3, 2025
New data from an ongoing study shows that a synthetic adeno-associated virus (AAV)-based gene therapy can improve hearing in individuals with congenital condition autosomal recessive deafness 9. It evaluated ten participants aged between one and 24 years old with a genetic form of deafness or severe hearing impairment caused by OTOF gene mutations. This results in otoferlin deficiency, a protein with a key role in transmitting auditory signals from the ear to the brain.
STAT
JULY 3, 2025
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: MoonLake Immunotherapeutics : Results from the sonelokimab Phase 3 VELA studies in hidradenitis suppurativa. Cogent Biosciences : Readout in July from the bezuclastinib Phase 3 SUMMIT study in indolent systemic mastocytosis.
The Checkup by Singlecare
JULY 3, 2025
Wegovy (semaglutide) is a prescription medication that’s approved by the Food and Drug Administration (FDA) to help with weight management in people ages 12 years and older with obesity and in adults who are overweight with at least one weight-related comorbid condition. It has also been approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease who are overweight or have obesity.
Pharmaceutical Commerce
JULY 3, 2025
Bruce Leuchter, CEO, Neurvati, discusses why patient engagement is essential to understanding rare diseases and driving the development of breakthrough therapies.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The Checkup by Singlecare
JULY 3, 2025
Veozah is a brand-name prescription medication that’s approved by the Food and Drug Administration (FDA) to treat symptoms of menopause , including vasomotor symptoms (VMS), such as hot flashes and night sweats. Its active ingredient is fezolinetant, a nonhormonal drug that helps balance estrogen levels and improve the body’s ability to regulate temperature.
Pharmaceutical Commerce
JULY 3, 2025
The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient needs through domestic innovation and capacity.
The Checkup by Singlecare
JULY 3, 2025
Blood thinners , which include anticoagulants and antiplatelet drugs , are medications that interfere with blood clot formation, either by slowing down clotting factors or preventing platelets from clumping. These medications are used after cardiac events such as heart attacks and strokes to treat blood clots or to lower the risk of blood clots. While anticoagulants are only available by prescription, a few antiplatelet medications are available over the counter (OTC) and can be purchased at a l
pharmaphorum
JULY 3, 2025
Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?
Fierce Healthcare
JULY 3, 2025
A collection of cities and advocacy groups has found issue with ACA enrollment changes set to take effect in late August.
pharmaphorum
JULY 3, 2025
Colorectal cancer patients could soon have access via the NHS to a targeted oral drug that can give them more precious time with their loved ones
Fierce Healthcare
JULY 3, 2025
Private equity investor Nordic Capital has acquired healthcare data analytics company Arcadia. Nordic will become the company's majority owner, which marks an exit for former investor Peloton Equity.
pharmaphorum
JULY 3, 2025
Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.
Dr. Jamie Hardy: The Lifestyle Pharmacist
JULY 3, 2025
You’ve mastered the art of showing up at work, for your family, in your community, all without missing a beat. This month, I want you to pause and consider this: How often do you make space to feel before you jump into action, or to rest before you give again? Minority Mental Health Month is about more than awareness. It’s also about reclaiming your right to be whole mentally, emotionally, and physically, in a world that often expects you to be unbreakable.
Fierce Healthcare
JULY 3, 2025
Centene pulled back its guidance for the year after an actuarial report suggested its growth in the ACA marketplaces will be slower than expected.
STAT
JULY 3, 2025
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I’m not sure if this newsletter is beach-reading material, but I hope you enjoy the long July Fourth weekend, wherever you’re taking it. And if you want to look ahead to what’s coming this quarter, my third quarter scorecard is out.
Fierce Healthcare
JULY 3, 2025
The deal gives the integrated care delivery company control of a health plan, multiple medical groups, an acute care hospital and other assets it said will synergize with its business.
pharmaphorum
JULY 3, 2025
Skip to main content Thursday 3 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Oncology -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -Wh
Pharmaceutical Technology
JULY 3, 2025
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
Pharmacy Times
JULY 3, 2025
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to
Expert insights. Personalized for you.
247 
Let's personalize your content